Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$6.1B
13M shares
52-week range
$365.21 – $508.71
68% from low
Sector
SERVICES-HOME HEALTH CARE SERVICES
Exchange
NYSE
CS
Borrow rate
0.41%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.78B | $1.94B | $2.08B | $2.14B | $2.13B | $2.26B | $2.43B | $2.53B |
| Cost of revenue | $1.23B | $1.32B | $1.38B | $1.37B | $1.37B | $1.47B | $1.58B | $1.77B |
| Gross profit | $555.0M | $617.4M | $701.4M | $769.8M | $765.1M | $798.8M | $854.3M | $758.3M |
| Gross margin | 31.1% | 31.8% | 33.7% | 36.0% | 35.8% | 35.3% | 35.1% | 30.0% |
| R&D | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Operating income | $243.6M | $257.4M | $389.7M | $343.0M | $343.5M | $340.6M | $366.5M | $338.2M |
| EBITDA | $283.5M | $311.3M | $454.9M | $411.2M | $393.4M | $414.3M | $464.3M | $422.4M |
| Net income | $205.5M | $219.9M | $319.5M | $268.6M | $249.6M | $272.5M | $302.0M | $265.2M |
| Net margin | 11.5% | 11.3% | 15.4% | 12.6% | 11.7% | 12.0% | 12.4% | 10.5% |
| EPS (diluted) | 12.23 | 13.31 | 19.48 | 16.85 | 16.53 | 17.93 | 19.89 | 18.42 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $2.7B | $24.34 | $23.93–$24.75 | 2 |
| 2027 | $2.9B | $26.88 | $26.09–$27.67 | 2 |
| 2028 | $3.0B | $28.85 | $28.72–$28.96 | 1 |
Forward consensus · source: Financial Modeling Prep
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
www.chemed.comNo one on the platform currently holds CHE.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 12,340 | $4.7M |
| Bridgewater Associatesas of 2026-03-31 | 5,062 | $1.9M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-28 | $0.6000 | 2026-06-16 |
| 2026-02-23 | $0.6000 | 2026-03-13 |
| 2025-11-17 | $0.6000 | 2025-12-05 |
| 2025-08-11 | $0.6000 | 2025-08-29 |
| 2025-05-29 | $0.5000 | 2025-06-17 |
| 2025-02-24 | $0.5000 | 2025-03-14 |
| 2024-11-18 | $0.5000 | 2024-12-06 |
| 2024-08-12 | $0.5000 | 2024-08-30 |
| 2024-05-30 | $0.4000 | 2024-06-18 |
| 2024-02-23 | $0.4000 | 2024-03-15 |
No one on the platform has traded CHE yet.
| $14.1B |
| — |
| HSICHenry Schein, Inc. | $84.29 | -0.78% | $9.6B | — |
| MTSRMetsera, Inc. | $70.50 | -0.35% | $7.4B | — |
Source: Financial Modeling Prep · peers by sector/industry
| 2023-11-10 |
| $0.4000 |
| 2023-12-04 |
| 2023-08-11 | $0.4000 | 2023-09-05 |
| Execution date | Ratio |
|---|---|
| 2005-05-12 | 2-for-1 |
Trading at 22.5× earnings vs its 29.0× historical median P/E.
Fair value ≈ $596.56 · price $462.50 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$CHE Put Open Interest Shifts for Chemed Corp This Week https://www.macroaxis.com/stock-options/CHE/Chemed-Corp?utm_source=dlvr.it&utm_medium=stocktwits
View on StockTwits ↗$CHE Really good write-up that perfectly summarizes CHE's present situation. So if you want to bring your CHE knowledge up to date or just discover CHE, this is required reading. https://everyticker.com/quote/CHE/analysis/chemed-s-asymmetric-turnaround-why-vitas-recovery-and-roto-rooter-resilience-make-this-dual-engine-story-compelling-nyse-che
View on StockTwits ↗Wall St is expecting 5.63 EPS for $CHE Q2 [Reporting 07/29 AMC] http://www.estimize.com/intro/che?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗Fundamental analysis of $CHE (CHEMED CORP) based on financial data and reported results. #CHE #CHEMED
View on StockTwits ↗$CHE (+8.4% pre) Chemed (CHE) Beats Q1 Earnings and Revenue Estimates https://ooc.bz/l/99915
View on StockTwits ↗After Hours Top Gainers PT2 $HKPD $TIVC $CISS $PDFS $CHE
View on StockTwits ↗$CHE Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $4.85 down -1.22% YoY • Reported revenue of $657.51M up 1.63% YoY • Chemed raised full-year 2026 adjusted diluted EPS guidance to $24.00-$24.75, reflecting improved VITAS performance. However, Roto-Rooter's adjusted EBITDA margin guidance was lowered to 21.5%-22.5% due to elevated marketing costs.
View on StockTwits ↗Wall St is expecting 5.30 EPS for $CHE Q1 [Reporting 04/23 AMC] http://www.estimize.com/intro/che?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗$CHE just got crushed — and this isn’t just a “small miss.” ⚠️ Shares slipped 15% after Q4 earnings and revenue both missed estimates, margins contracted, and the 2026 EPS outlook came in below consensus. That’s a triple hit to confidence. When growth stalls and guidance disappoints at the same time, the market reprices fast. See the full breakdown and what this means for the stock 👉 https://www.zacks.com/stock/news/2877001/che-stock-falls-post-q4-earnings-revenue-miss-margins-crash?cid=sm-stocktwits-2-2877001-teaser-35586&ADID=SYND_STOCKTWITS_TWEET_2_2877001_TEASER_35586
View on StockTwits ↗$CHE drops 15% post-earnings — what’s the downturn about? 📉 Chemed's Q4 adjusted EPS of $6.42 missed the Zacks Consensus Estimate by 8.55%, with revenues also falling short by 2.55%. VITAS saw revenue growth, while Roto-Rooter faced a decline, alongside margin contraction. Full insights here 👉 https://www.zacks.com/stock/news/2877001/che-stock-falls-post-q4-earnings-revenue-miss-margins-crash?cid=sm-stocktwits-2-2877001-body-35587&ADID=SYND_STOCKTWITS_TWEET_2_2877001_BODY_35587
View on StockTwits ↗$CHE I know little to nothing about this stock and company. Apparently none of miss was baked in?? It was at 24 x trailing before this slaughter going sub 20. I would think after a substantial short attack cuz noone will stand up on the bid, it will deadcat for a nice trade. Gonna be watching it
View on StockTwits ↗$CHE Q4 '25 Earnings Results & Recap • Reported GAAP EPS of $5.48 down -9.87% YoY • Reported revenue of $639.34M down -0.10% YoY • Chemed estimates full-year 2026 adjusted diluted EPS between $23.25 and $24.25, with VITAS revenue projected to increase 5.5% to 6.5% and Roto-Rooter revenue growth of 3.0% to 3.5%.
View on StockTwits ↗Wall St is expecting 5.99 EPS for $CHE Q1 [Reporting 04/29 AMC] http://www.estimize.com/intro/che?chart=historical&metric_name=eps&utm_cont
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.